Concord Biosciences Holdings, Inc. HRMY shares are buying and selling larger on Monday because the inventory rebounds after falling Friday on Section 3 INTUNE examine information.
What To Know: Shares of Concord fell final Friday after the corporate introduced topline outcomes from the INTUNE examine on pitolisant in sufferers with idiopathic hypersomnia. Concord famous no statistically important distinction was noticed between pitolisant and placebo on ESS. On Monday, shares recovered by over 11%.
Moreover, three analysts lowered their value targets on the inventory on Monday.
- Raymond James analyst Danielle Brill maintained Concord Biosciences with a Outperform and lowered the value goal from $58 to $26.
- Needham analyst Ami Fadia maintained Concord Biosciences with a Purchase and lowered the value goal from $66 to $53.
- Piper Sandler analyst David Amsellem maintained Concord Biosciences with a Obese and lowered the value goal from $72 to $42.
Associated Hyperlink: Why DexCom Inventory Is Rising Throughout Monday’s Session
HRMY Value Motion: Shares of HRMY had been up 11.6% at $23.56 on the time of publication, in line with Benzinga Professional.
Picture by Jan from Pixabay
© 2023 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.
Supply Hyperlink : dianahutson.com